Skip to main content
Equibles

Cheryl R. Blanchard, Ph.D.

Board Member

Xilio Therapeutics, Inc. (XLO)

Equibles does not estimate personal net worth.

Get an email with a short summary when Xilio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get XLO alerts

About Cheryl R. Blanchard, Ph.D.

Cheryl R. Blanchard, Ph.D. is recorded as Board Member at Xilio Therapeutics, Inc. (XLO) since April 15, 2026. Xilio Therapeutics, Inc. reported in an 8-K filed April 16, 2026 that Cheryl R. Blanchard, Ph.D. was appointed Class III director, effective April 15, 2026. Xilio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Xilio Therapeutics, Inc. includes René Russo (CEO and Board Member), Sara M. Bonstein (Chairman and Board Member), Kevin Brennan (CFO and Chief Accounting Officer) and 7 others.

“On April 15, 2026, the Board of Directors (the "Board") of Xilio Therapeutics, Inc. (the "Company"), on the recommendation of the Nominating and Corporate Governance committee of the Board, elected Cheryl R. Blanchard, Ph.D., as a Class III director of the Company, with a term expiring at the Company's 2027 annual meeting of stockholders, to serve until her successor has duly been elected and qualified or until her earlier resignation, death or removal.”
Xilio Therapeutics, Inc. Form 8-K, filed April 16, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Xilio Therapeutics, Inc.

Recent activity